Oglesby A, et al. Patient-reported outcomes after switching to a two-drug regimen of dolutegravir + rilpivirine: Week 100 results from the SWORD-1 and SWORD-2 studies. Abstract P101. HIV/Drug Therapy Glasgow 2018.
Amsterdamse analyse toont dat COVID-19-gerelateerd ARDS heterogeen is
okt 2021 | Pneumonie, Virale infecties